U.S. Food and Drug Administration Approves EMSAM(R) (selegiline transdermal system), the First Transdermal Patch for (PR Newswire via Yahoo! Finance)
Bristol-Myers Squibb Company and Somerset Pharmaceuticals, Inc., a joint venture between Mylan Laboratories Inc. and Watson Pharmaceuticals, Inc., , announced today that the U.S. Food and Drug Administration approved EMSAM , the first transdermal patch for the treatment of major depressive disorder in adults.